Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Presentation

Poster: Anti-AAV6 antibody assay for patient enrollment supporting ST-920 phase 1/2 study for Fabry disease

Liching Cao, Sangamo Therapeutics

  • Poster Session: Thursday, February 8, 2024 – 3-5pm PT (Poster: 048)

Download PDF